# PATENT COOPERATION TREATY

REC'D 27 JAN 2006

# INTERNATIONAL PRELIMINARY REPORT ON PATENCABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Artcle 36 and Rule 70)

Γ	· · · · · · · · · · · · · · · · · · ·					
Applicant's or agent's file reference 4FPO-11-04	FOR FURTHER ACTION	N See	Form PCT/IPEA/416			
International application No. PCT/KR2004/003435	International filing date(day/n 24 DECEMBER 2004	· ·	ity date (day/month/year) DECEMBER 2003 (27.12.2003)			
International Patent Classification (IPC)			ECDIVIDEN 2003 (27.12.2003)			
C07D 307/68(2006.01)i	or national classification and I	rc				
Applicant  KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY et al						
This report is the international pre Authority under Article 35 and tra	insmitted to the applicant accor	ding to Article 36.	onal Preliminary Examining			
2. This REPORT consists of a total of	of 3 _sheets, incl	uding this cover sheet.				
<ul> <li>This report is also accompanied by ANNEXES, comprising:</li> <li>a. (sent to the applicant and to the International Bureau) a total ofsheets, as follows:</li> </ul>						
sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).						
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the						
Supplemental Box						
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in electronic form only, as indicated in the Supplemental Box relating to Sequence Listing (see Section 802 of the Administrative Instructions).						
This report contains indications re	lating to the following items:					
Box No. I Basis of the	-					
Box No. II Priority						
Box No. III Non-establi	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. V Reasoned s citations and	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain doc	Box No. VI Certain documents cited					
Box No. VII Certain defe	defects in the international application					
Box No. VIII Certain obse	Box No. VIII Certain observations on the international application					
Date of submission of the demand		e of completion of this rep	ort			
		_				
15 JULY 2005 (15	.07.2005)	13 JANUARY 2006	(13.01.2006)			
Name and mailing address of the IPEA/I	⟨R Aut	horized officer				
Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea		LIM, Hea Joon				
Facsimile No. 82-42-472-7140		phone No. 82-42-481-56	500			

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/KR2004/003435

Box No. 1 Basis of the report	
With regard to the language, this report is based on the international application in the la otherwise indicated under this item.	nguage in which it was filed, unless
This report is based on translations from the original language into the following la	
which is the language of a translation furnished for the purposes of:	anguage,
international search (under Rules 12.3 and 23.1(b))	
publication of the international application (under Rule 12.4)	
international preliminary examination (under Rules 55.2 and/or 55.3)	
international profitminary examination (under Rules 55.2 and/or 55.3)	
<ul> <li>With regard to the elements of the international application, this report is based on (replace to the receiving Office in response to an invitation under Article 14 are referred to in this rannexed to this report):</li> <li>the international application as originally filed/furnished</li> </ul>	ement sheets which have been furnished eort as "originally filed" and are not
the description:	
pages	
pages* received by this Authority on	as originally filed/furnished
pages* received by this Authority on	
the claims:	
pages	as originally filed/furnished
ከያለያያቸ	r with any statment) under Article 19
pages* received by this Authority on	
<u></u> -	
the drawings:	•
pages	as originally filed/furnished
pages* received by this Authority on	
pages* received by this Authority on	
the sequence listing and/or any related table(s) - see Supplemental Box Relating to Sec	quence Listing.
3. The amendments have resulted in the cancellation of:	
the description, pages	
I I the claims Nos	
the drawings sheets	
the drawings, sheets the sequence listing (specify)	
any table(s) related to sequence listing (specify):	
4. This report has been established as if (some of) the amendments annexed to this report made, since they have been considered to go beyond the disclosure as filed, as indicate (Rule 70.2(c)).  the description, pages the claims, Nos.	ed in the Supplemental Box
the drawings shoots	
the drawings, sheets	
the sequence fisting (specify):	
any table(s) related to sequence listing (specify):	
* If item 4 applies, some or all of those sheets may be marked "superseded."	
11 - A	ĺ

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/KR2004/003435

Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability:
	citations and explanations supporting such statement

1.	Statement			
	Novelty (N)	Claims	1-10 YES	
		Claims	NO	
	Inventive step (IS)	Claims	1-10 YES	
		Claims	NO	
	Industrial applicability (IA)	Claims	1-10 YES	
		Claims	NO	

## 2. Citations and explanations (Rule 70.7)

Reference is made to the following documents:

D1 = US 5627193 A (06. 05. 1997)

D2 = US 6630506 B1 (07. 10. 2003)

D3 = W0 03-101450 A1 (11. 12. 2003)

D4 = W0 99-33460 (08.07.1999)

The present invention relates to furancarbonylguanidine derivatives which can be used as a NHE-1 inhibitor, a preparation method thereof and a pharmaceutical composition comprising the same.

D1 discloses quinoline-4-carbonylguanidine derivative and a preparation method therof and a NHE inhibitor containing the same. D2 discloses acyl guanidines which are used as NHE inhibitors. D3 discloses N-((3-oxo 2,3-dihydro-1H-isoindol-1-yl)acetyl)guanidine derivatives as NHE-1 inhibitors for the treatment of infarction and angina pectoris. D4 discloses acyl guanidine sodium/proton exchange inhibitors and method.

### 1. Novelty

None of the prior art disclose the compound of formula(1) claimed in the present invention and their property. Therefore, the present invention seems to be novel(PCT Article 33(2)).

### 2. Inventive Step

Although D1-D5 disclose the compounds showing a similar pharmaceutical activity as the compounds of the present invention, neither structural variation nor combination of different structural features of compounds disclosed therein lead to the structural properties as those described in the present invention. Thus the present invention is regarded as being inventive according to PCT Article 33(3).

## 3. Industrial Applicability

The present invention meets the criteria set out in PCT Article 33(4).